首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients
Authors:Romain Guery  Stephen L Walker  Gundel Harms  Andreas Neumayr  Pieter Van Thiel  Jean-Pierre Gangneux  Jan Clerinx  Sara Karlsson Sbirk  Leo Visser  Laurence Lachaud  Mark Bailey  Aldert Bart  Christophe Ravel  Gert Van der Auwera  Johannes Blum  Diana N Lockwood  Pierre Buffet  on behalf of the LeishMan Network and the French Cutaneous Leishmaniasis Study group
Abstract:BackgroundCutaneous leishmaniasis (CL) is frequent in travellers and can involve oro-nasal mucosae. Clinical presentation impacts therapeutic management.MethodologyDemographic and clinical data from 459 travellers infected in 47 different countries were collected by members of the European LeishMan consortium. The infecting Leishmania species was identified in 198 patients.Principal findingsCompared to Old World CL, New World CL was more frequently ulcerative (75% vs 47%), larger (3 vs 2cm), less frequently facial (17% vs 38%) and less frequently associated with mucosal involvement (2.7% vs 5.3%). Patients with mucosal lesions were older (58 vs 30 years) and more frequently immunocompromised (37% vs 3.5%) compared to patients with only skin lesions. Young adults infected in Latin America with L. braziliensis or L. guyanensis complex typically had an ulcer of the lower limbs with mucosal involvement in 5.8% of cases. Typically, infections with L. major and L. tropica acquired in Africa or the Middle East were not associated with mucosal lesions, while infections with L. infantum, acquired in Southern Europe resulted in slowly evolving facial lesions with mucosal involvement in 22% of cases. Local or systemic treatments were used in patients with different clinical presentations but resulted in similarly high cure rates (89% vs 86%).Conclusion/SignificanceCL acquired in L. infantum-endemic European and Mediterranean areas displays unexpected high rates of mucosal involvement comparable to those of CL acquired in Latin America, especially in immunocompromised patients. When used as per recommendations, local therapy is associated with high cure rates.
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号